We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Momenta, Sandoz Tell U.S. High Court Hatch-Waxman Patent Safe Harbor Is Not Too Narrow

(August 11, 2016, 3:23 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court should not hear a petition to consider whether an appellate court’s interpretation of the Hatch-Waxman safe harbor, 35 U.S. Code Section 271(e)(1), is “overly narrow” and puts generic manufacturers at risk of patent suits, Momenta Pharmaceuticals Inc. argue in an Aug. 1 opposition brief (Amphastar Pharmaceuticals, Inc., et al. v. Momenta Pharmaceuticals, Inc. and Sandoz, Inc., No. 15-1402, U.S. Sup.).

(Respondents’ opposition brief available. Document #78-160815-005B.)

The Federal Circuit U.S. Court of Appeals ruled Nov. 10 that although a...
To view the full article, register now.